drugset / Trial / NCT02357342

Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMD

NCT02357342

Phase 2 Completed 40 enrolled Maturi, Raj K., M.D., P.C.
RandomizedParallel-groupSingle-blindTreatment

Summary

Phase 2 clinical trial, single site, randomized, subject-masked study to determine safety and efficacy of intravitreal injections of Sirolimus in subjects with wet Age-Related Macular Degeneration (wet AMD) with persistent intraretinal or subretinal edema due to neovascular AMD despite previous AntiVEGF treatment.

Timeline

Start
2015-04
Primary completion
2017-01
Completion
2017-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aflibercept Protein / enzyme biologic Intravitreal
Comparator Bevacizumab Monoclonal antibody Intravitreal
Subject Sirolimus Small molecule Intravitreal